Chorionic Gonadotropin, beta Subunit, Human ; blood ; Down Syndrome ; blood ; diagnosis ; Female ; Humans ; Pregnancy ; Pregnancy, Twin ; Prenatal Diagnosis ; alpha-Fetoproteins ; metabolism

Apoptosis ; Brain Neoplasms ; genetics ; pathology ; Cell Proliferation ; Genes, Retinoblastoma ; genetics ; Genes, erbB-1 ; genetics ; Genes, p53 ; genetics ; Glioma ; genetics ; pathology ; Humans ; Inhibitor of Growth Protein 1 ; Intracellular Signaling Peptides and Proteins ; genetics ; Mutation ; Nuclear Proteins ; genetics ; Tumor Suppressor Proteins ; genetics

Child ; Coronary Aneurysm ; complications ; Humans ; Male ; Mucocutaneous Lymph Node Syndrome ; complications ; Multiple Organ Failure ; complications ; Shock ; complications

Objective To systematically evaluate the safety of high dose atorvastatin (80 mg daily) in Chinese patients. Methods Randomized controlled trials (RCTs) investigating 80 mg/ d atorvastatin vs. low-dose atorvastatin or placebo or blank were electionically retrieved in date bases of EMbase, PubMed, the Cochrane Library, WanFang, CNKI and WeiPu. Meta-analysis was performed using RevMan 5. 2 and Stata 11. 0 software. Results A total of 20 RCTs involving 2282 cases were included. The results of meta-analysis showed no significant differences betweent the 80 mg/ d atorvastatin group and the control group in the incidence of gastrointestinal adverse events (RR 1. 53, 95% CI 0. 85-2. 76, P = 0. 16), hepatic adverse events (RR 1. 53, 95% CI 0. 99 - 2. 36, P = 0. 05), muscular adverse events (RR 1. 51, 95% CI 0. 92 -2. 49, P = 0. 10), serious hepatic injuries ( RR 2. 33,95% CI 0. 88 - 6. 20, P = 0. 09) and serious muscular myopathies (RR 1. 40, 95% CI 0. 46 - 4. 30, P = 0. 56). Subgroup analysis by type of cotrast media used and durations of taking 80 mg/ d atorvastatin showed there were higher risks of gastrointestinal adverse events in the 80 mg/ d group when compared to blank control ( RR 4. 22, 95% CI 1. 11 - 16. 04, P = 0. 03). Conclusions The current evidence shows that 80 mg / d atorvastatin may be relatively safe in terms of adverse events in gastrointestinal tract, liver and muscular system, and relatively has risk in causing severe liver injuries and myopathies. With limited quantity and quality from the RCTs available, more high quality RCTs are needed to verify the above conclusion.

Objective To investigate the cancer-related fatigues in oral cancer patients.Methods One hundred oral cancer patients were involved in the survey with self-designed general information questionnaire,revised Piper fatigue correction scale(RPFS).Results Seventy six cases(76.00%)had different degree of fatigue.The total score of RPFS was(5.51+1.23)points. In the descending order of scores,the dimensions were body fatigue,emotional fatigue,behavioral fatigue and cognitive fatigue. Conclusions Oral cancer patients have cancer-related fatigue commonly,with body fatigue the most intense and emotional fatigue at a higher level.Therefore,medical staff should ensure patients intake of enough nutrients in order to reduce the body fatigue and meanwhile should instruct patients to handle their bad moods correctly so as to relieve their metal fatigue.

Connexin 43 ; genetics ; Connexins ; genetics ; Heart Defects, Congenital ; genetics ; Homeobox Protein Nkx-2.5 ; Homeodomain Proteins ; genetics ; Humans ; Infant ; Infant, Newborn ; Mutation ; genetics ; Myocardium ; metabolism ; Transcription Factors ; genetics

Child ; Child, Preschool ; Female ; Heart Defects, Congenital ; metabolism ; Humans ; Male ; Troponin I ; metabolism

Arterio-Arterial Fistula ; therapy ; Cardiac Catheterization ; Coronary Vessels ; Female ; Heart Septal Defects, Ventricular ; therapy ; Heart Ventricles ; abnormalities ; Humans

Adult ; Chemical and Drug Induced Liver Injury ; Chronic Disease ; Critical Illness ; Dimethylformamide ; poisoning ; Humans ; Male ; Middle Aged ; Occupational Diseases ; chemically induced ; Occupational Exposure

Hearing Loss, Sudden ; diagnosis ; therapy ; Humans